Streetbeat News

Price Targets

JAZZ

Needham analyst Ami Fadia has reiterated a 'Buy' rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) and maintained a price target of $226.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:19 am

TRNS

HC Wainwright & Co. analyst Scott Buck maintains a 'Buy' rating on Transcat (NASDAQ:TRNS) and raises the price target from $102 to $106.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:16 am

PRQR

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on ProQR Therapeutics (NASDAQ:PRQR) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:15 am

FHTX

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Foghorn Therapeutics (NASDAQ:FHTX) and maintained a $20 price target.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:14 am

SAGE

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Neutral rating on Sage Therapeutics (NASDAQ:SAGE) and maintained a $50 price target.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:13 am

ACIU

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on AC Immune (NASDAQ:ACIU) and maintained a $16 price target.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:13 am

VIR

HC Wainwright & Co. analyst Patrick Trucchio maintains a 'Buy' rating on Vir Biotechnology (NASDAQ:VIR) but lowers the price target from $100 to $95.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:08 am

ALNY

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $405.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:07 am

SAND

HC Wainwright & Co. analyst Heiko Ihle maintains a 'Buy' rating on Sandstorm Gold (NYSE:SAND) and raises the price target from $12.5 to $13.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:05 am

CLMT

HC Wainwright & Co. analyst Amit Dayal has reiterated a 'Buy' rating on Calumet Specialty Prods (NASDAQ:CLMT) and maintained a $25 price target.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:04 am